Insulin glargine 300 U/mL versus first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 12‐month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real‐life clinical trial

AIM: To report the effectiveness and safety of insulin glargine 300 U/mL (Gla‐300) versus standard‐of‐care basal insulin analogues (SOC‐BI) at 12 months in the ACHIEVE Control trial, which is a prospective pragmatic randomized real‐life study in insulin‐naïve adults with type 2 diabetes (T2D). METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Meneghini, Luigi, Blonde, Lawrence, Gill, Jasvinder, Dauchy, Arnaud, Bacevicius, Andrius, Strong, Jodi, Bailey, Timothy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689721/
https://www.ncbi.nlm.nih.gov/pubmed/32538550
http://dx.doi.org/10.1111/dom.14116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689721/
https://www.ncbi.nlm.nih.gov/pubmed/32538550
http://dx.doi.org/10.1111/dom.14116

Ejemplares similares